Bergerac Systems: The Challenge of Backward Integration Custom Case Solution & Analysis

Evidence Brief

1. Financial Metrics

Cartridge procurement costs represent 40 percent of total cost of goods sold for the diagnostic line (Exhibit 1).
Genocorp proposed a 12 percent price increase for the upcoming fiscal year (Paragraph 4).
Acquisition cost for Genocorp is estimated at 35 million dollars (Exhibit 5).
Internal manufacturing setup requires a 25 million dollar capital investment (Exhibit 5).
Bergerac annual revenue stands at approximately 480 million dollars with a 14 percent net margin (Exhibit 2).
Projected savings from backward integration total 8 million dollars annually starting in year two (Exhibit 6).

2. Operational Facts

Genocorp supplies 80 percent of the plastic cartridges used in the Bergerac flagship product (Paragraph 2).
Current defect rates from Genocorp reached 15 percent in the last quarter, causing 48 hours of total production downtime (Exhibit 3).
Lead times for cartridge delivery increased from 14 days to 32 days over the last 12 months (Paragraph 8).
Bergerac currently holds 0 percent internal expertise in high-precision plastic injection molding (Paragraph 10).
The Genocorp facility operates at 70 percent capacity, leaving room for expansion (Exhibit 4).

3. Stakeholder Positions

James (CEO): Prioritizes supply chain security and margin expansion to meet board expectations for the next fiscal year.
Greis (CFO): Expresses concern regarding the 35 million dollar cash outlay and prefers a phased internal build to preserve liquidity.
Taylor (VP Operations): Demands immediate resolution of quality issues to prevent further damage to the diagnostic equipment brand reputation.
Genocorp Management: Willing to sell but insists on retaining current operational staff for a three year transition period.

4. Information Gaps

The case does not specify the intellectual property ownership of the cartridge designs.
There is no data on the cost of alternative suppliers outside the current geographic region.
The specific terminal value of the Genocorp facility after ten years is not provided.

Strategic Analysis

1. Core Strategic Question

Should Bergerac Systems acquire its primary supplier, Genocorp, or build internal manufacturing capacity to mitigate supply chain risk and rising costs?

2. Structural Analysis

Supplier power is the primary threat to Bergerac profitability. The 80 percent reliance on Genocorp creates a bottleneck where price hikes and quality failures directly impact the bottom line. High switching costs and specialized technical requirements for medical-grade plastics limit the ability to diversify quickly. The industry is moving toward vertical integration to capture the 25 percent margin currently held by component manufacturers. Porter s Five Forces analysis confirms that supplier power is high, while the threat of new entrants is low due to regulatory barriers.

3. Strategic Options

Option	Rationale	Trade-offs	Resource Requirements
Acquire Genocorp	Immediate control over supply and quality with existing infrastructure.	High upfront cost and integration risk of a different corporate culture.	35 million dollars and a dedicated integration team.
Build Greenfield Facility	Full control over technology and 10 million dollars cheaper than acquisition.	18 to 24 month delay before production begins; lack of internal expertise.	25 million dollars and recruitment of specialized engineering talent.
Dual Sourcing Strategy	Reduces dependency without large capital expenditure.	Does not solve the margin capture problem or the 12 percent price hike.	Procurement team expansion and vendor qualification costs.

4. Preliminary Recommendation

Bergerac must acquire Genocorp immediately. The 15 percent defect rate and 12 percent price increase represent an existential threat to the diagnostic line. Building a greenfield facility takes too long, leaving Bergerac vulnerable for two years. Acquisition provides immediate access to the 30 percent excess capacity at Genocorp, allowing Bergerac to scale production and capture the supplier margin immediately. The 10 million dollar premium over the build option is justified by the avoidance of production downtime and the immediate stabilization of the supply chain.

Implementation Roadmap

1. Critical Path

Month 1: Finalize due diligence and execute the 35 million dollar purchase agreement.
Month 2: Appoint a new Quality Director at the Genocorp facility to overhaul the injection molding process.
Month 3: Integrate financial reporting and procurement systems between Bergerac and the new subsidiary.
Month 4: Initiate a 5 million dollar equipment upgrade to reduce the 15 percent defect rate to under 2 percent.
Month 6: Transition 100 percent of cartridge production to the internal subsidiary and terminate remaining third party contracts.

2. Key Constraints

Technical Talent Retention: The success of the acquisition depends on keeping the Genocorp engineering team who understand the proprietary molding processes.
Regulatory Compliance: Any change in manufacturing location or process requires re-validation by medical authorities, which can delay the transition by months.

3. Risk-Adjusted Implementation Strategy

The plan assumes a 20 percent buffer in the timeline for regulatory approvals. To mitigate the risk of talent flight, Bergerac will implement a three year retention bonus structure for key Genocorp engineers. If quality targets are not met by month four, a secondary contingency fund of 3 million dollars is allocated to hire external consultants to stabilize the manufacturing line. This approach prioritizes operational stability over immediate cost savings.

Executive Review and BLUF

1. BLUF

Acquire Genocorp for 35 million dollars immediately. The current 15 percent defect rate and 12 percent price increase from the primary supplier jeopardize the flagship diagnostic line. Waiting to build an internal facility creates a two year window of unacceptable risk. This acquisition secures the supply chain, captures supplier margins, and provides the capacity needed for future growth. The 10 million dollar premium over building a facility is a necessary cost for immediate operational control and risk mitigation.

2. Dangerous Assumption

The analysis assumes that the 15 percent defect rate is caused by poor management or aging equipment that can be fixed with capital. If the defects are inherent to the Genocorp design or material science, the acquisition will not solve the quality problem and Bergerac will have purchased a failing asset.

3. Unaddressed Risks

Integration Friction: The cultural gap between a high-growth medical device firm and a small manufacturing shop may lead to a loss of key personnel within the first six months. High probability. High consequence.
Regulatory Delay: The time required to re-certify the Genocorp facility under Bergerac ownership could extend beyond the projected six months. Moderate probability. High consequence.

4. Unconsidered Alternative

The team did not evaluate a joint venture with a global plastics manufacturer. This would allow Bergerac to share the 25 million dollar capital risk while gaining access to world class expertise without the burden of full ownership and management of a non-core manufacturing process.